Follistatin-344 Price Comparison — Compare 5 Vendors
Price Comparison
Compare vendors · per 1mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| SomaChems7/10 | $79.99 | $79.99 | May 14, 2026 | Buy → |
| CertaPeptides7.5/10 | $122.00 | $122.00 | Jun 27, 2026 | Buy → |
| Core Peptides5.5/10 | $138.00 | $138.00 | Apr 16, 2026 | Buy → |
| Biotech Peptides6/10 | $162.00 | $162.00 | May 14, 2026 | Buy → |
| LeoLab Rx6/10 | $170.00 | $170.00 | Apr 6, 2026 | Buy → |
Research details
Follistatin-344 — research data
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Overview
About Follistatin-344
Mechanism of action
Endogenous glycoprotein; binds and inhibits activin and myostatin; reduces myostatin-mediated muscle growth inhibition; promotes satellite cell activation and muscle fiber hypertrophy.
Safety profile
Significant risk: unregulated muscle growth, organ growth, cardiovascular strain; limited human safety data; potential cancer promotion via activin inhibition. · Documented central serous chorioretinopathy (vision impairment) case at a 10x dose; possible FSH suppression and theoretical fibrosis risk with chronic TGF-β inhibition; ~38 kDa glycoprotein with minimal injectable-peptide human data (most evidence is gene therapy). WADA-banned.
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Follistatin-344 below your target.
Related pages
More on Follistatin-344
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Follistatin directly binds and neutralizes myostatin with a high-affinity Kd of ~5.84 × 10⁻¹⁰ M; the full follistatin protein is required for binding, and follistatin dose-dependently rescued muscle cell differentiation blocked by myostatin by restoring expression of Pax-3 and MyoD in chick developmental models.
- A Phase 1/2a clinical trial delivered follistatin via AAV1 intramuscular injection to six Becker muscular dystrophy patients; results showed improved 6-minute walk test scores (up to +125 m in some patients), reduced fibrosis, decreased central nucleation, and enlarged muscle fiber cross-sectional area at higher doses, with no serious adverse events.